Projet GLIOTRAIN (Horizon 2020, appel à projets 2017)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : CLOSED

Glioblastoma (GBM) is the most frequent, aggressive and lethal of all brain tumours. It has a universally fatal prognosis with 85% of patients dying within two years. New treatment options and effective precision medicine therapies are urgently required. This can only be achieved by focused multi-sectoral industry-academia collaborations in newly emerging, innovative research disciplines. GLIOTRAIN will exploit the intractability of GBM to address European applied biomedical research training needs. The ETN, which comprises 9 beneficiaries and 14 partner organisations from 8 countries, will train 15 innovative, creative and entrepreneurial ESRs. The research objective of GLIOTRAIN is to identify novel therapeutic strategies for application in GBM, while implementing state of the art next generation sequencing, systems medicine and integrative multi-omics to unravel disease resistance mechanisms. Research activities incorporate applied systems medicine, integrative multi-omics leveraging state of the art platform technologies, and translational cancer biology implementing the latest clinically relevant models. The consortium brings together leading European and international academics, clinicians, private sector and not-for-profit partners across GBM fields of tumour biology, multi-omics, drug development, clinical research, bioinformatics, computational modelling and systems biology. Thus, GLIOTRAIN will address currently unmet translational research and clinical needs in the GBM field by interrogating innovative therapeutic strategies and improving the mechanistic understanding of disease resistance. The GLIOTRAIN ETN addresses current needs in academia and the private sector for researchers that have been trained in an environment that spans translational research, medicine and computational biology, and that can navigate confidently between clinical, academic and private sector environments to progress applied research findings towards improved patient outcomes.

Mots clés : multi omics, glioblastoma, preclinical models, mathematical modelling, data integration

Participants :
- Yumab gmbh (Allemagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Vlaams Instituut voor Biotechnologie (Belgique) — Partner, beneficiary, Recherche, subvention : 667672.8 €
- Insilico Biotechnology (Germany) (Allemagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- University of Stuttgart (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 498432.96 €
- Royal College of Surgeons in Ireland (Irlande) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 1062698.4 €
- KU Leuven (Belgique) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Bristol myers squibb (France) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Pepscope bv (Pays-Bas) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Champions oncology, inc. (Etats-Unis) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Mimetas (Netherlands) (Pays-Bas) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Information technology for translational medicine (ittm) sa (Luxembourg) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 250560.0 €
- Erasmus MC (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 510748.56 €
- Luxembourg Institute of Health (Luxembourg) — Partner, beneficiary, Recherche, subvention : 250560.0 €
- GeneXplain (Germany) (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 249216.48 €
- Agilent Technologies (Belgium) (Belgique) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 84007.2 €
- International brain tumour alliance (Royaume-Uni) — Partner, organization partner, Autres, subvention : 0.0 €
- University of Luxembourg (Luxembourg) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Cancer Trials Ireland (Irlande) — Partner, organization partner, Autres, subvention : 0.0 €
- Hannover Medical School (Allemagne) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Oncurious nv (Belgique) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Carthera (France) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Institut du cerveau (France) — Partner, beneficiary, Recherche, subvention : 262875.6 €
- Teva pharmaceuticals europe b.v. (Pays-Bas) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €